Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)
Trial · NCT05854784
Results by group11
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 11 of 11
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Change in Disease Severity in Patients With VP as Measured by CGIC. | Afamelanotide | 2.5 | Full Range 1.0 to 3.0 | Scores on a scale | |
| The Change in Disease Severity in Patients With VP as Measured by 11-point VAS IGA. | SCENESSE® (Afamelanotide 16mg) | -3.0 | Full Range -5.0 to 0.0 | Scores on a scale | |
| The Change in Disease Severity in Patients With VP as Measured by 5-point IGA. | SCENESSE® (Afamelanotide 16mg) | -2.0 | Full Range -3.0 to 1.0 | Scores on a scale | |
| The Change in Disease Severity in Patients With VP as Measured by PGIC. | SCENESSE® (Afamelanotide 16mg) | 2.5 | Full Range 1.0 to 3.0 | Scores on a scale | |
| The Change in Disease Severity in Patients With VP as Measured by PGA Using VAS. | SCENESSE® (Afamelanotide 16mg) | -6.5 | Full Range -9.0 to -1.0 | Scores on a scale | |
| The Change in Number of New Skin Lesions Formed. | SCENESSE® (Afamelanotide 16mg) | -6.5 | Full Range -11.0 to 4.0 | Lesions | |
| The Change in the Quality of Life in Patients With VP as Measured by WPAI:GH. | SCENESSE® (Afamelanotide 16mg) | -10.00 | Full Range -80.0 to 40.0 | Percentage of impairment time | |
| The Change in the Quality of Life in Patients With VP as Measured by VP-derived QOLEB. | SCENESSE® (Afamelanotide 16mg) | -12.0 | Full Range -23.0 to -3.0 | Score on a scale | |
| The Change in the Quality of Life in Patients With VP as Measured by VP QoL. | SCENESSE® (Afamelanotide 16mg) | Baseline | 0 | Participants | |
| The Change in the Quality of Life in Patients With VP as Measured by VP QoL. | SCENESSE® (Afamelanotide 16mg) | Day 168 | 5 | Participants | |
| The Change in Outdoor Light Exposure Over Time (Daily Diary) | SCENESSE® (Afamelanotide 16mg) | 0.70 | Full Range 0.2 to 2.3 | Change in number of hours of sunlight |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05854784/results